Scarica l'app Stockscreener
0.595
8.18%
0.045
Dopo l'orario di chiusura:
.57
-0.025
-4.20%
Precedente Chiudi:
$0.55
Aprire:
$0.5457
Volume 24 ore:
194.42K
Relative Volume:
0.05
Capitalizzazione di mercato:
$4.85M
Reddito:
$88,000
Utile/perdita netta:
$-13.96M
Rapporto P/E:
-0.0894
EPS:
-6.6545
Flusso di cassa netto:
$-11.34M
1 W Prestazione:
-13.96%
1M Prestazione:
-22.98%
6M Prestazione:
-77.52%
1 anno Prestazione:
+392.23%
Intervallo 1D:
$0.54
$0.6099
Intervallo di 1 settimana:
$0.53
$0.7749
Portata 52W:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Nome
AIM ImmunoTech Inc
Settore
Industria
Telefono
352 448 7797
Indirizzo
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.595 | 4.85M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Why did AIM stock more than double in pre-market today? - msn.com
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval - MEXC
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
AIM ImmunoTech announces final approval of novel cancer therapy patent in Japan combining Ampligen with checkpoint inhibitors - marketscreener.com
Aim Immunotech Announces Final Approval Of Novel Cancer Therapy Patent In Japan Combining Ampligen With Checkpoint Inhibitors - TradingView
AIM ImmunoTech (AIM) CEO converts Series G preferred into 25,000 common shares - Stock Titan
AIM ImmunoTech (AIM) director converts Series G preferred into 25,000 shares - Stock Titan
AIM ImmunoTech (AIM) director gets Series G preferred and 50,000 warrants - Stock Titan
AIM ImmunoTech Inc. Signs Dealer-Manager Agreement with Maxim Group LLC for Rights Offering – SEC Form 8-K Filing March 2026 - Minichart
AIM ImmunoTech completes rights offering, creates new preferred stock series By Investing.com - Investing.com Australia
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
AIM ImmunoTech Announces Closing of its Rights Offering - Caledonian Record
AIM ImmunoTech Completes Series G Preferred Rights Offering - TipRanks
AIM ImmunoTech completes rights offering, creates new preferred stock series - Investing.com
AIM ImmunoTech Inc Azioni (AIM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):